BioSpace News Archive

The American Association of Oral and Maxillofacial Surgeons and the Henry Schein Cares Foundation are supporting the volunteer service of four oral and maxillofacial surgeons through the joint Global Outreach Program.

OBI Pharma announced the initiation of a Phase 1/2 clinical trial of OBI-999, an antibody drug conjugate targeting Globo H, a glycolipid antigen overexpressed in multiple tumor types.

Ipsen announced that David Meek has resigned as the company’s Chief Executive Officer and will step down from the Board of Directors, effective December 31, 2019, to pursue another professional opportunity as President and Chief Executive Officer of FerGene.

FerGene, a new gene therapy company launched by Ferring Pharmaceuticals and Blackstone Life Sciences in November, announced the appointment of David Meek as President and Chief Executive Officer, effective January 14, 2020.

MODAG announced the clinical trial initiation of, and recruitment for, a first-in-human Phase 1 study of lead candidate, anle138b in healthy volunteers.

LHC Group, Inc. (NASDAQ: LHCG) and Ochsner Health System (Ochsner) announced an expansion of their joint venture partnership – Southeast Louisiana HomeCare – with an agreement to purchase five Egan Home Health and Hospice provider locations across South Louisiana.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will provide a corporate update and also participate in a Lunch Plenary Panel titled: “Reshaping the life sciences and healthcare landscape: The impact of pricing, policy and payers”

Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa

The National Council of State Boards of Nursing Board of Directors (NCSBN BOD) voted on Dec. 9, 2019, to raise the passing standard for the NCLEX-PN Examination (the National Council Licensure Examination for Practical Nurses).

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority’s (NJEDA) New Jersey Technology Business Tax Certificate Transfer program.